Portland, OR Clinical Trials Report — May 2026

For Portland residents considering participation in clinical research, May 2026 brings both urgent opportunities and significant new avenues for contributing to medical science. Across Portland, OR, a number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 47 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as only 1 of these rapidly closing studies is still actively seeking participants without specific health conditions. This trial offers a chance to contribute to medical advancements before its enrollment window closes.

Urgent Opportunities: Trials Closing Soon

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Ovarian cancer (2 trials)
• Advanced breast cancer (2 trials)
• Glaucoma (2 trials)
• Prostate cancer (2 trials)
• Breast cancer (2 trials)
• Acute undifferentiated leukemia (1 trial)
• Acute myeloid leukemia (1 trial)
• Acute blood loss anemia (1 trial)
• ALS-frontotemporal dementia (1 trial)
• Advanced solid tumor (1 trial)

New Research Horizons in Portland

This month, Portland saw the opening of 13 new clinical trials, an increase from the 12 trials that launched in April 2026. This brings the total number of actively recruiting clinical trials in Portland, OR, to 980 across 324 research facilities, underscoring the city's robust research landscape.

May brings several high-profile new trials to Portland, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• AstraZeneca is sponsoring NCT07611110, "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)." This Phase 3 study, involving 670 participants, intends to demonstrate the superiority of AZD2265 relative to standard of care treatments for metastatic castration-resistant prostate cancer.
• Eli Lilly and Company is leading NCT07589595, "A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)." This Phase 2 study with 350 participants aims to evaluate whether treatment with donanemab slows the progression of cognitive and functional decline.
• Another significant Phase 2 trial from AstraZeneca is NCT07608354, "A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM." This study involves 326 participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
• Oregon Health and Science University is sponsoring NCT07601841, "Light Therapy to Improve Sleep in TBI: Sleep-active Biomarkers and Glymphatic Function." This study, with 300 participants, examines how improved sleep through morning bright light therapy impacts brain health processes like mitochondrial function, systemic inflammation, and glymphatic function.
• Also from Oregon Health and Science University, NCT07594145, "Precision T1D Platform - New Therapies for Cardio-Renal Complications," is a Phase 2 study with 57 participants focusing on cardio-renal complications in Type 1 Diabetes.

New trials this month are exploring a range of conditions, with notable additions including amyloid, traumatic brain injuries, cancer, cardio-renal vascular function and failure, cognitive dysfunction, eating disorders in children, functional limitation, glymphatic system, heart failure, and hematopoietic and lymphatic system neoplasm. Drug trials account for the largest share of new studies, with 8 new drug trials, followed by 2 device trials and 2 other types of studies.

Leading sponsors for these new trials include Oregon Health and Science University (3 trials) and AstraZeneca (3 trials), alongside contributions from Eli Lilly and Company, Novo Nordisk A/S, OHSU Knight Cancer Institute, and others. Industry sponsors account for 7 of the new trials, with academic and other sponsors contributing 6.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are opportunities to contribute to research. A total of 2 of the 13 new trials launched this month are actively seeking healthy volunteers. Across Portland, a total of 70 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Portland's Leading Research Institutions

Portland is home to some of Oregon's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Oregon Health and Science University (including OHSU Knight Cancer Institute and Oregon Health Sciences University) collectively leads with a significant presence, totaling over 398 trials.
• Providence Portland Medical Center (123 trials)
• Providence Saint Vincent Medical Center (93 trials)
• Research Site (35 trials)
• Legacy Good Samaritan Hospital and Medical Center (24 trials)
• Providence St. Vincent Medical Center (23 trials)
• Kaiser Permanente Northwest (19 trials)
• Legacy Emanuel Children's Hospital (18 trials)
• VA Portland Health Care System, Portland, OR (17 trials)

These institutions offer a broad spectrum of research, from oncology at OHSU Knight Cancer Institute and Providence facilities, to diverse medical fields across the Oregon Health and Science University system and other major hospitals.

Diverse Participation and Nearby Options

Participation in clinical trials is open to a diverse range of individuals. Of the 13 new trials launched this month, 10 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, 1 is female-only, and 3 are male-only.

While Portland offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Oregon. For example, Gresham currently has 1 active trial.

As we move further into spring, Portland's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and explore new treatment options.